NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, detailing continued progress of its broad-spectrum antiviral candidate NV-387. The company has obtained regulatory approval to move NV-387 into Phase II clinical development for MPox in the Democratic Republic of Congo. This milestone marks a significant step toward addressing the global health concern of MPox, which has seen outbreaks in recent years.
Beyond MPox, the company outlined its orphan-first regulatory strategy, which already yielded FDA orphan drug designation for measles subsequent to the quarter. Additional orphan drug applications are pending for MPox and smallpox, potentially accelerating development timelines and providing market exclusivity. The strategy leverages the fact that orphan drug designation offers incentives such as tax credits and seven-year market exclusivity upon approval.
NV-387 is designed as a broad-spectrum antiviral with potential applications against respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, in addition to MPox/smallpox and measles. The company believes its nanoviricide platform, based on TheraCour nanomedicine technology, enables targeted delivery and enhanced efficacy against a wide range of viruses.
NanoViricides also highlighted its ongoing efforts to advance NV-387 into Phase II human clinical trials, focusing on the most pressing viral threats. The company’s pipeline includes other candidates such as NV-HHV-1 for shingles and NV-CoV-2 for COVID-19, which does not encapsulate remdesivir, as well as NV-CoV-2-R, which encapsulates remdesivir. The company notes that remdesivir is already FDA-approved, potentially facilitating a smoother regulatory path for NV-CoV-2-R if safety is comparable.
The company’s platform technology is licensed from TheraCour Pharma, Inc., with exclusive rights for several antiviral applications. NanoViricides holds a worldwide exclusive perpetual license for treating HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses pending successful research.
Despite these advancements, NanoViricides acknowledges the inherent risks in drug development, noting that the path to commercialization is lengthy and capital-intensive. There is no guarantee that any of its candidates will demonstrate sufficient safety and efficacy in clinical trials or receive regulatory approval. However, the company’s progress in obtaining regulatory approvals and orphan designations underscores its commitment to addressing unmet medical needs across multiple viral diseases.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/osO0q.
